Portola Pharmaceuticals (NASDAQ:PTLA): Q2 GAAP EPS of -$0.97 beats by $0.05.
Revenue of $28.4M (+608.2% Y/Y) beats by $2.98M.
Shares +1.3%.
Wednesday, August 7, 2019
Sangamo Q2 revenue down 18%
Sangamo Therapeutics (NASDAQ:SGMO) Q2 results:
Revenues down 18% to $17.5M primarily due to a change in estimate resulting from the expansion of its agreement with Pfizer in hemophilia A.
Net loss: ($30.3M); loss/share: ($0.26).
Shares down 1% after hours.
Previously: Sangamo Therapeutics EPS beats by $0.08, beats on revenue(Aug. 7)
CymaBay Therapeutics EPS beats by $0.02
CymaBay Therapeutics (NASDAQ:CBAY): Q2 GAAP EPS of -$0.35 beats by $0.02.
Cash, cash equivalents and marketable securities of $241.2M.
Wright Medical EPS beats by $0.01, misses on revenue
Wright Medical (NASDAQ:WMGI): Q2 Non-GAAP EPS of $0.02 beats by $0.01; GAAP EPS of -$0.15 beats by $0.08.
Revenue of $229.73M (+11.8% Y/Y) misses by $3.31M.
Dermira EPS beats by $0.62, beats on revenue
Dermira (NASDAQ:DERM): Q2 GAAP EPS of -$0.33 beats by $0.62.
Revenue of $66.65M (+70.5% Y/Y) beats by $38.39M.
Shares +3.25%.
Catalyst Pharmaceuticals EPS beats by $0.07, beats on revenue
Catalyst Pharmaceuticals (NASDAQ:CPRX): Q2 GAAP EPS of $0.10 beats by $0.07.
Revenue of $28.84M beats by $10.85M.
Shares +9.16%.
MyoKardia EPS beats by $0.17
MyoKardia (NASDAQ:MYOK): Q2 GAAP EPS of -$0.83 beats by $0.17.
Cash and cash equivalents of $443.69M.
Subscribe to:
Posts (Atom)